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Fetal Cells in Maternal Blood
Current methods of prenatal diagnosis include
amniocentesis and chorionic villus sampling, with a
miscarriage risk of 0.5–2% [1]. Significant effort is thus
being made to develop noninvasive diagnostic
procedures. Various kinds of fetal cells are known to
circulate in maternal peripheral blood, including
trophoblasts, erythrocytes, and leukocytes, and these
provide a potential source of fetal genes for prenatal
DNA diagnosis. However, trophoblasts and leukocytes
appear at minute concentrations in maternal circulation.
Furthermore, fetal leukocytes are difficult to distinguish
from maternal leukocytes and continue to exist for
several years after delivery [2]. Conversely, as nucleated
erythrocytes (NRBCs) are not commonly found in the
peripheral blood of normal adults, as they are the most
abundant fetal cells found in maternal circulation, and
as they have a limited life span in maternal blood, they
are considered suitable targets for noninvasive prenatal
genetic diagnosis.
Over the last decade or so, numerous investigators
have attempted to isolate fetal cells from maternal
blood using various cell-separation techniques, including
fluorescence-activated cell sorting (FACS) [3,4],
magnetic-activated cell sorting (MACS) [5], galactose-
specific lectin [6], and micromanipulation [7,8].
However, methods for detecting NRBCs in all cases
have not been established. The major limitation in
applying these techniques clinically is the generally low
number of fetal cells found in maternal blood (about 1
fetal cell/mL maternal blood) [9]. The National Institutes
of Health initiated a Phase II clinical investigation
(National Institutes of Health Fetal Cell Study, NIFTY
trial) to assess the diagnostic efficiency of determining
fetal gender and aneuploidies using fetal NRBCs from
maternal blood [10]. The rate of predicting fetal gender
was only 41% among aneuploid fetuses [10], although
the number of fetal cells detectable in the maternal
circulation is higher in some aneuploid fetuses [9].
Therefore, this clinical trial indicated the limitations of
prenatal diagnosis using fetal NRBCs in maternal
circulation. NRBCs are currently considered difficult to
use for noninvasive prenatal diagnosis, a situation that
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will only be remedied with the development of new
technical innovations.
Plasma Fetal DNA and Use in Prenatal
DNA Diagnosis
A new area of research has developed following the
discovery of large amounts of circulating cell-free fetal
DNA in maternal plasma or serum. In 1997, Lo et al
demonstrated that cell-free fetal DNA circulates in the
plasma or serum of pregnant women [11]. A real-time
polymerase chain reaction (PCR) system was used to
quantify the amount of fetal DNA by targeting SRY, a
single-copy Y chromosome-specific sequence present
when the pregnant woman carries a male fetus [12].
Surprisingly, high mean concentrations of fetal DNA
(3.4–6.2%) were demonstrated in total maternal plasma
DNA. The mean concentration of fetal DNA was 25.4
copies/mL of maternal plasma at early gestation, much
higher than that for fetal cells in maternal blood [12].
We quantified fetal DNA in the plasma of 156
pregnant women at 7–16 weeks. Median concentration
of fetal DNA in plasma was 36.5 genome-equivalents
(GE)/mL [13]. Since the half-life of fetal DNA in maternal
plasma is reportedly 16.3 minutes [14], this DNA offers
a suitable target for prenatal DNA diagnosis and is not
affected by any previous pregnancies.
Fetal DNA was initially used for determination of
fetal gender [12,13] and fetal Rhesus D (RhD) blood
type [15]. When Y chromosome-specific sequences were
detectable, the fetus was considered male. When such
sequences were not detected, the fetus was considered
female. Fetal gender was assessed using maternal blood
samples from 302 pregnant women at 7–16 weeks of
gestation. The Y chromosome-specific DYS14 sequence
was amplified using real-time quantitative PCR, and
fetal gender was determined thereafter. Fetal gender
was determined in 298 of 302 pregnant women with
overall sensitivity, specificity and positive and nega-
tive predictive values for a male fetus of 97.2%, 100%,
100%, and 97.5%, respectively [13]. Fetal gender deter-
mination using maternal plasma thus offers an accu-
rate and reliable method for pregnant women at 7
weeks or more of gestation. Knowing the fetal gen-
der through noninvasive procedures can reduce the
number of invasive procedures required to examine
X-linked genetic disorders.
Fetal DNA in maternal plasma has been used to
detect fetal RhD status in RhD-negative pregnant women
[15]. Lo et al analyzed 57 plasma samples from RhD-
negative pregnant women, achieving accurate diagno-
sis of fetal RhD blood type in 45 samples obtained in
the second trimester or later. They concluded that
noninvasive fetal RhD genotyping can be performed
rapidly and reliably using maternal plasma beginning in
the second trimester of pregnancy [15]. When the
father is heterozygous for the RhD gene and the mother
is RhD-negative, prenatal determination could prove
clinically useful, as no further testing or therapeutic
procedures would be necessary if the fetus was confirmed
as RhD-negative.
Next, in 2000, we achieved noninvasive prenatal
DNA diagnosis of a single-gene disorder, achondroplasia
(ACH), using maternal plasma [16]. This disorder is the
most common genetic form of dwarfism and is inherited
as an autosomal dominant gene, although most cases
are sporadic [17]. Shiang et al demonstrated that more
than 90% of ACH patients display the same missense
mutation in the transmembrane domain of the fibroblast
growth factor-receptor 3 (FGF-R3) gene, comprising a
G-A or G-C transition at nucleotide (nt) 1138 [17].
We investigated prenatal DNA diagnosis of ACH
using plasma from a woman at 30 weeks of gestation
whose fetus displayed suspected short-limb disorder on
ultrasonography. Maternal plasma DNA was extracted
and the segment of FGF-R3 containing nt1138 was
amplified by PCR using specific primers and conditions
[17]. PCR products were restricted using SfcI to detect
a G-A transition at nt1138. The ACH mutation creates
an SfcI site such that, upon digestion, two extra bands
of 111 and 55 base pairs are generated. This process
revealed that DNA from maternal plasma contained the
mutant allele [16]. Recently, Amicucci et al achieved
prenatal diagnosis of myotonic dystrophy from maternal
plasma [18]. In at-risk pregnancies, prenatal exclusion
of cystic fibrosis, ` -thalassemia, and congenital adrenal
hyperplasia using analysis of fetal DNA in maternal
blood has been described [19–21].
This shows that a fetal-derived mutant gene can be
detected in maternal plasma for prenatal diagnosis of
single-gene disorders caused by paternally inherited
genes or mutations that are distinguishable from
maternally inherited counterparts. However, this plasma
DNA approach only allows examination of disorders
where the gene of interest is present in the fetal genome
but absent from the maternal DNA.
Fetal DNA Concentration and Complications
of Pregnancy
Pre-eclampsia
Lo et al reported that fetal DNA concentration is
elevated in the plasma of pregnant women with pre-
eclampsia [22], and concluded that measurement of
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circulating DNA may prove useful as a marker for
diagnosis and/or monitoring of this condition. Zhong
et al also reported that levels of cell-free fetal and
maternal DNA increase in the plasma of pregnant women
with pre-eclampsia [23]. Likewise, we found that fetal
DNA was increased in plasma from pregnant women
with pre-eclampsia, but not in plasma from pregnant
women with fetal growth restriction (FGR) without pre-
eclampsia [24]. However, higher fetal DNA values have
been reported in a selected population of fetuses with
abnormal uterine arteries on Doppler ultrasonography
[25].
The pathogenesis of pre-eclampsia is poorly under-
stood, but is probably associated with failure of the
uterine vasculature to undergo adequate physiologic
remodeling by extravillous trophoblasts [26]. Insufficient
invasion of extravillous trophoblasts into the uterine
vasculature results in no reduction in placental vascular
resistance, causing inadequate oxygenation of blood
within the placental intervillous spaces bordering vil-
lous trophoblasts. This might damage the villous
trophoblasts, leading to the release of DNA from cell
damage or apoptosis into the intervillous spaces, and
from there into the maternal circulation [27].
Fetal DNA in maternal plasma might be able to show
placental damage, so we examined whether fetal DNA
levels in maternal plasma are associated with severity of
pre-eclampsia. Estimated fetal DNA concentrations were
2.25- and 5.06-fold greater in patients with mild and
severe pre-eclampsia, respectively, than in controls. We
also examined relationships between proteinuria and
hypertension and fetal DNA values. We found that both
proteinuria and hypertension were independently and
strongly associated with increased concentrations of
fetal DNA in maternal plasma, and that proteinuria was
associated with greater increases in fetal DNA than
hypertension. These findings support previous reports
that proteinuria in pre-eclampsia is more closely
associated with FGR or placental dysfunction than
hypertension. Total DNA concentrations in maternal
plasma were further assessed by analyzing the `-globin
gene, revealing that `-globin levels in the plasma of
pregnant women with pre-eclampsia were fourfold high-
er than in controls [28]. Among pre-eclampsia cases,
concentrations in cases with FGR were almost double
those in cases without FGR [28]. These findings indicate
that `-globin concentrations in maternal plasma are
associated with the severity of pre-eclampsia.
Leung et al reported that fetal DNA concentrations
are elevated in the plasma of pregnant women who go
on to develop pre-eclampsia [29]. We also reported
that fetal DNA levels were 2.39-fold greater in preg-
nancies that later develop pre-eclampsia compared
with matched controls (at about 20 weeks of gestation).
Furthermore, `-globin levels in the plasma of pregnant
women around 20 weeks prior to the appearance of
clinical symptoms of pre-eclampsia were approximately
double those of controls [30]. When fetal DNA, total
DNA or both values were used in predicting pre-
eclampsia, detection rates were 33%, 46%, and 62%,
respectively, with a 5% false-positive rate [30]. Plasma
DNA concentration can thus potentially be used for
early prediction of pre-eclampsia.
Hyperemesis gravidarum
We speculated that the pathogenesis of hyperemesis
gravidarum (HG) would yield an increased level of fetal
DNA in maternal plasma, as hyperactivation of the
maternal immune system destroys fetal trophoblasts.
To confirm this hypothesis, the relationship between
cell-free fetal DNA concentration and clinical severity
of HG was assessed. HG was classified into three cate-
gories according to disease severity: mild (nausea and
vomiting but no need for hospitalization), moderate
(admission for HG with hydration requiring infusion
therapy but lacking all criteria that define severe HG),
and severe (admission for HG with ketonuria > 3+ based
on urine dipstick test, and weight loss > 3 kg). Blood
samples were obtained from 45 patients with HG for
quantification of fetal DNA concentrations. Fetal DNA
levels in mild, moderate, and severe HG were found to
be 1.26-, 1.62-, and 2.41-fold higher, respectively, than
in controls [31,32].
Although the pathogenesis of HG is obscure,
Minagawa et al reported that functional activation of
natural killer and cytotoxic T cells is more prominent in
the blood and uterine decidua of women with HG than
in women with uncomplicated pregnancy [33]. Hyper-
activation of the maternal immune system may be
responsible for the onset of HG, probably while mater-
nal immune tolerance to the semi-allograft is being
established. As fetal DNA primarily originates from
placental trophoblasts, this theory is concordant with
the finding that severity of HG is related to fetal DNA
levels [32].
Invasive placenta (abnormal adherence of the
placenta)
We speculated that the invasion of trophoblasts into
the uterine musculature in patients with invasive placenta
would result in increased concentrations of cell-free
fetal DNA within maternal plasma, as trophoblasts
might be destroyed by the maternal immune system
upon invasion into muscle tissue. Fetal DNA levels were
assessed in two patients with invasive placenta.
Concentrations of fetal DNA in both cases appeared
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higher than in gestational age-matched controls. This
suggested that antenatal detection of invasive placenta
might be achievable through analysis of fetal DNA
concentrations in maternal plasma [34]. Furthermore,
we reported a case of placenta increta in which a small
part of the placenta remained adherent despite manual
removal of the placenta at the time of delivery. The
patient was followed-up by monitoring plasma
concentrations of `-human chorionic gonadotropin
(`-hCG) and fetal DNA levels after delivery [35]. In this
patient, fetal DNA was detected until 10 weeks after
delivery, whereas plasma `-hCG could not be detected
after 11 days postpartum. Intermittent vaginal bleeding
continued until fetal DNA was no longer detectable in
plasma. This indicated that concentrations of fetal
DNA in plasma might offer a useful marker for follow-
up of patients with retained placental tissue after deliv-
ery [35].
Preterm delivery
Leung et al reported that fetal DNA is present at higher
concentrations in the plasma of pregnant women with
preterm labor who deliver preterm than in those who
deliver at term [36]. This finding has recently been
confirmed in a high-risk population by Farina et al, who
found that early preterm delivery (< 30 weeks) had a
higher cumulative probability of occurring (45%) in
subjects with higher fetal DNA concentrations, while
only 14% of cases delivered prematurely in the presence
of lower fetal DNA values [37].
Fetal trisomy 21
Lo et al reported that concentrations of cell-free DNA
increase in the plasma and serum of pregnant women
with a trisomy-21 fetus [38]. Zhong et al reported that
fetal DNA levels are significantly elevated in pregnancies
with trisomy 21, but not in those with trisomy 18 [39].
Farina et al statistically confirmed, in a matched case-
control study, that fetal DNA in maternal serum from
the second trimester is associated with a detection rate
of about 20% and a false-positive rate of 5% for detect-
ing Down syndrome cases [40]. However, Ohashi et al
reported that levels of fetal DNA in maternal serum do
not differ between pregnancies with fetuses of normal
karyotype and those with trisomy 18 or 21 [41], and the
elevation of fetal DNA in plasma or serum from mothers
carrying aneuploid fetuses thus remains controversial. If
fetal DNA levels in maternal plasma are significantly
elevated in pregnant women with aneuploid fetuses,
quantitative analyses of these levels may serve as an
additional marker for some fetal chromosomal
abnormalities. Real-time quantitative PCR assay of
circulating fetal DNA in maternal blood provides a
powerful means of not only detecting fetal DNA in
maternal plasma or serum, but also for studying the
conditions of pathologic pregnancies.
Origin of Fetal DNA in Maternal Plasma
The origin of fetal DNA remains controversial. Possible
sources for fetal DNA in maternal plasma include:
destruction of fetal cells in maternal blood, trans-
placental transfer of fetal cell-free DNA, and destruc-
tion of villous trophoblasts bordering the intervillous
space.
We have previously observed apoptotic changes in
43% of fetal NRBCs circulating in maternal blood,
finding that the high oxygen concentrations in maternal
circulation induce apoptotic changes in fetal NRBCs
transferred to maternal blood [42,43]. We speculate
that apoptosis is the mechanism by which fetal cells are
cleared from maternal circulation without maternal
inflammatory responses during pregnancy, and that
fetal cells in maternal blood represent a source of fetal
DNA in maternal plasma. However, concentrations of
fetal NRBCs in maternal blood are much lower than
those of fetal DNA in maternal plasma [12]. The
concentration of fetal DNA in maternal plasma re-
portedly does not increase in plasma samples extracted
from blood after 24 hours [44]. Furthermore, although
the number of fetal NRBCs in maternal blood is elevated
in pregnant women with FGR [45], cell-free fetal DNA
concentration is not [24]. Fetal DNA concentrations
are reportedly elevated in women with preterm labor
[36], but the number of fetal NRBCs in maternal cir-
culation is not elevated in such cases [46]. These facts
indicate that the mechanism leading to elevated fetal
DNA concentrations in maternal plasma differs from
that increasing fetal cell numbers in maternal blood.
Most fetal DNA thus appears not to be derived from
transferred fetal NRBCs in maternal blood.
To assess transplacental transfer of fetal cell-free
DNA, we evaluated bidirectional transfer of plasma
DNA between maternal and fetal circulations. Cell-free
fetal DNA concentrations in maternal plasma were
much higher than maternal DNA concentrations in
umbilical plasma, and cell-free maternal DNA con-
centrations in fetal circulation were unaffected by pre-
eclampsia, which is associated with trophoblastic
damage and subsequent elevated fetal DNA con-
centrations in the plasma of pregnant women. These
findings indicate that plasma cell-free DNA is unequally
transferred between fetal and maternal circulations. We
conclude that cell-free fetal DNA transferred from fetal
circulation would be limited in maternal plasma.
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The remaining source of fetal DNA is the tro-
phoblasts. In the placenta, villous trophoblasts border
the intervillous space, which is filled with maternal
blood (Figure). In pre-eclampsia, insufficient invasion
by extravillous trophoblasts is related to hypoxic
damage to villous trophoblasts, inducing apoptosis
[47]. Apoptosis is frequently detected by TUNEL
staining in the syncytiotrophoblasts of placentas from
pre-eclamptic patients [48]. Cell-free and fragmented
DNA is likely to be structurally released into the
intervillous space. Apoptosis of villous trophoblasts
has been observed even in normal pregnancies. Villous
trophoblasts are very important for maintenance
of placental function. Functional and structural cha-
racteristics of the placenta appear likely to be re-
sponsible for the high concentrations of fetal DNA in
maternal plasma. Furthermore, as mentioned above,
we have previously reported elevated concentrations of
fetal DNA in the maternal plasma of women with
placenta previa, particularly in those with invasive
placenta [34]. In these cases, trophoblasts invading
the uterine musculature are attacked and destroyed by
the maternal immune system, resulting in increased
levels of fetal DNA in maternal plasma. This suggests
that most cell-free fetal DNA in the plasma of pregnant
women originates from the damage and destruction of
trophoblasts.
Conclusion
Circulating fetal DNA in maternal plasma can be
used for both fetal genetic testing and evaluation of
the complications of pregnancy. In prenatal genetic
testing, lack of risk represents the greatest advantage
of this approach. However, the target for diagnosis
is limited to genes not possessed maternally, such as
Y chromosome-specific genes or RhD genes in RhD-
negative pregnant women. Since most fetal DNA appears
to originate from villous trophoblasts, concentrations
can be used to evaluate damage to trophoblasts, parti-
cularly in pathologic complications of pregnancy. Fetal
DNA in the plasma of pregnant women thus offers a
new source of data that can be used in various clinical
settings.
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